OLMAOlema Pharmaceuticals, Inc.
$7.81-25% 1Y
$7.81
$7.7752 weeks$35.83
OLMA in its own filings
Nothing in OLMA's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
114
Events found in the filings · across 560 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 13, 2026
Most recent filing · Form 8-K
- Record starts
- Oct 16, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity13 occurrences
- 2025-01-13
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026On August 13, 2026, Olema Pharmaceuticals, Inc. (the “Company”) announced the appointment of Jason O’Byrne as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, which was approved by the Board of Directors of the Company (the “Board”) on July 28, 2026 and effective as …Director or officer change · Form 8-K
- Aug 10, 2026Olema Oncology Reports Second Quarter 2026 Financial and Operating Results.Earnings release · press release
- May 26, 2026As described above, on May 26, 2026, the Company announced that it had entered into the Agreement with Bayer.Regulation FD disclosure · Form 8-K
- May 21, 2026As described above, on May 21, 2026, the Company announced preliminary clinical data from its Phase 1 study of OP-3136.Regulation FD disclosure · Form 8-K
- May 12, 2026Olema Oncology Reports First Quarter 2026 Financial and Operating Results.Earnings release · press release
- May 1, 2026On April 27, 2026, Olema Pharmaceuticals, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with KR Oyster Point II, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease an aggregate of approximately 38,176 square feet, consisting of 25,048 square feet of …Material agreement entered · Form 8-K
- Apr 29, 2026On April 27, 2026, upon recommendation from the Nominating and Corporate Governance Committee (the “Nominating Committee”) of the Board of Directors (the “Board”) of Olema Pharmaceuticals, Inc. (the “Company”), the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026 (the …Director or officer change · Form 8-K
- Mar 16, 2026Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results.Earnings release · press release
- Jan 30, 2026On January 30, 2026, Olema Pharmaceuticals, Inc. (the “Company”) announced that Shane Kovacs, the Company’s Chief Operating and Financial Officer, is departing the Company effective January 30, 2026 (the “Separation Date”) to pursue new opportunities.Director or officer change · Form 8-K
- Jan 12, 2026Advancing medicines for breast cancer and beyond Corporate Overview January 2025.Earnings release · press release
- Nov 19, 2025Follow-On Public Offering On November 18, 2025, Olema Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…